🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseNon-invasive MASH biomarkers — anyone have experience? Page 2

Non-invasive MASH biomarkers — anyone have experience?

dave_SLC Thu, Jan 15, 2026 at 10:26 PM 8 replies 872 viewsPage 2 of 2
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Jan 16, 2026 at 12:01 AM#6
JessicaH_TX said:
Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD).

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

Last edited: Jan 16, 2026 at 3:01 AM
35 5steve_okc, dave_SLC, FDA_TrackerJim and 32 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Jan 16, 2026 at 12:38 AM#7
dave_SLC said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
34 4stefan_berlin, Dr.EM_Chicago, pete_RVA and 31 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jan 16, 2026 at 1:15 AM#8
kate.chem said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

There is a second half to this that has not been said yet. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Jan 16, 2026 at 4:15 AM
33 3DataDave, Dr.GutHealth, amsterdam_pete and 30 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Jan 16, 2026 at 1:52 AM#9

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

Last edited: Jan 16, 2026 at 4:52 AM
32 2marco_milano, pam_columbus, nick_SD_fit and 29 others
Reply Quote Save Share Report
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Jan 16, 2026 at 4:50 AM#10

Closing the loop on my own question.

Update, and it is the boring outcome: nothing was wrong. The measurement I was reading had moved less than its own week-to-week variation, which somebody said upthread and I did not believe.

14 12Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 11 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register